Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Fraud and scandal in biotech

Nature Biotechnology volume 24, pages 745–747 (2006)Cite this article

To the editor:

The revelation at the beginning of the year that Woo Suk Hwang faked some of the results of some high-profile and widely reported cloning experiments1,2 was predicted to have deleterious effects on the confidence in science across the world3. It was also portrayed in some media circles as indicative of the pernicious influence of commercial interests on the integrity of the scientific enterprise.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Biotech in the news.
Figure 2: Analysis of articles by subject.

References

  1. Cyranoski, D. Nature 438, 718 (2005).

    Article  CAS  Google Scholar 

  2. Holden, C. Science 310, 1402–1403 (2005).

    Article  CAS  Google Scholar 

  3. Check, E. & Cyranoski, D. Nature 438, 1056 (2005).

    Article  CAS  Google Scholar 

  4. Aldersley-Williams, H. White coats don't lie ... do they? The Independent (London) August 26 (1996), p. 16.

    Google Scholar 

  5. Dalyell, T. Why should the public trust science? The Guardian (London) March 13 (1997), p. 3.

    Google Scholar 

  6. Griffith, V. Sorting science fiction from fact: the third of a series looking at scientific regulation, Victoria Griffith examines efforts to cut fraud. Financial Times (London) April 8 (1999), p. 21.

    Google Scholar 

  7. Gibb, E. Dark side of science beneath the white coats. The Sunday Herald (Edinburgh) April 9 (2000), p. 2.

    Google Scholar 

  8. Ingham, J. The fatal errors as science sells out to big business. Daily Express (London) February 29 (2000), p. 2.

    Google Scholar 

  9. Barlow, T. When good ideas begin to go bad. Financial Times (London) June 30 (2000), p. 2.

    Google Scholar 

  10. Barlow, T. When the devil invites you to dine. Financial Times (London) May 26 (2000), p. 2.

    Google Scholar 

  11. Barlow, T. Take some mice and a black felt pen. Financial Times (London) May 19 (2001), p. 2.

    Google Scholar 

  12. Wootlif, B. Wanted: Chief Executive to run British biotech company. The Business (London) November 10 (2002), p. 19.

    Google Scholar 

  13. Anon (editorial). Nat. Biotechnol. 24, 1 (2006).

  14. Verjee, N. & Davies, C. Need to know: the week ahead. The Times (London) March 7 (2005), p. 38.

    Google Scholar 

  15. Anon, ImClone scandal drug submitted for approval. The Times. London. August 16 (2003), p. 3.

  16. Clow, R., G. Dyer & H. Yeager A high society sale. Financial Times (London) June 15 (2002), p. 15.

    Google Scholar 

  17. Hughes, D. & Pfeifer, S. The great ImClone share sell-off scandal. The Business (London) June 17 (2002), p. 13.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Rufus Scientific, 37 The Moor, Melbourn, Royston, SG8 6ED, Herts, UK

    William Bains

Authors
  1. William Bains
    View author publications

    You can also search for this author in PubMed Google Scholar

Supplementary information

Supplementary Fig. 1

See how they run: longevity of story-lines. (PDF 39 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bains, W. Fraud and scandal in biotech. Nat Biotechnol 24, 745–747 (2006). https://doi.org/10.1038/nbt0706-745

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt0706-745

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing